Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Travere Therapeutics, Inc. Common Stock

TVTX

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Last trade $50.86
Day change +$1.15 (+2.32%)
Day range $46.35 – $51.14
Volume 715,670
Market cap $4.77B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.77B
Price / earnings
—
Price / book
211.25×
Price / sales
7.33×
EV / sales
8.07×
EV / EBITDA
-65.06×

Profitability

Earnings per share
-$1.27
Return on assets
-14.32%
Return on equity
-538.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
26.72×
Current ratio
3×
Quick ratio
2.95×
Cash ratio
0.59×

Cash flow

Price / cash flow
27.02×
Price / free cash flow
74.72×
Free cash flow
$63.85M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TVTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$224.56M$169.58M$127.2M$129.69M$164.86M$114.45M$81.73M$74.79M
Cost of revenue$2.87M$2.17M$1.95M$2.55M$1.59M$1.52M$4.68M$2.55M
Gross profit$221.7M$167.41M$125.25M$127.14M$163.27M$112.93M$77.05M$72.23M
Selling, general and administrative$98.41M$96.11M$80.25M$101.69M$71.05M$62.58M$60.41M$69.5M
Research and development$183.42M$60.28M$57.09M$57.87M$51.89M$49.36M$46.89M$62.07M
Total operating expenses$289.8M$163.46M$162.16M$159.56M$138.34M$125.58M$119.73M$132.97M
Operating income-$68.11M$3.95M-$36.92M-$32.43M$24.93M-$12.65M-$42.67M-$60.74M
Interest expense-$2.14M-$2.13M-$2.3M-$2.3M-$2.75M-$2.85M-$2.86M-$2.82M
Income before taxes-$66.93M-$35M-$36.72M-$21.07M$25.71M-$12.74M-$41.19M-$60.34M
Income taxes-$5.9M-$204K-$120K$921K$8K$20K$39K-$72K
Net income-$52.34M-$34.8M-$37.1M$2.73M$25.71M-$12.76M-$41.23M-$60.26M
Net income attributable to common shareholders-$52.34M-$34.8M-$37.1M$2.73M$25.71M-$12.76M-$41.23M-$60.26M
EBITDA-$62.91M$8.19M-$11.7M-$14.29M$40.72M$1.37M-$29.87M-$47.24M
Basic earnings per share-$0.55-$0.37-$0.40$0.03$0.29-$0.14-$0.47-$0.72
Diluted earnings per share-$0.55-$0.37-$0.40$0.04$0.28-$0.14-$0.47-$0.72

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings

Travere Therapeutics reported Q3 2026 revenue of $224.56 million, up 36.2% year-over-year and beating consensus estimates by 16.64%. However, the company posted an EPS of -$0.55, significantly missing the -$0.25 consensus estimate. FILSPARI product sales surged 120.2% to $200.19 million, but license and collaboration revenue declined 91.6%. The stock carries a Zacks Rank #5 (Strong Sell) rating and has underperformed the market by 10.6% over the past month.

Zacks Investment Research

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) reported a quarterly loss of $0.55 per share, significantly missing the consensus estimate of $0.25 loss, representing a -120% earnings surprise. While revenues of $224.56 million exceeded expectations by 16.64%, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends. The stock is expected to underperform the market in the near term despite outperforming the S&P 500 by 31.9% year-to-date.

Zacks Investment Research

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +0.44% and Zacks Rank #3 (Hold). The company is projected to report a quarterly loss of $1.50 per share with revenues of $42.01 million, up 2065.5% year-over-year. The stock has beaten consensus EPS estimates in 2 of the last 4 quarters.

Zacks Investment Research

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

AstraZeneca announced FDA approval of Ultomiris (ravulizumab) for reducing proteinuria in adults with primary IgAN at risk of disease progression. This marks the drug's fifth U.S. indication and makes it the first C5 complement inhibitor approved for this use. Ultomiris sales grew 14% to $2.58 billion in H1 2026, though the company faces competition from Calliditas, Novartis, and Travere in the IgAN market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.